Abstracts Archive - Page 266 of 2607 - ACR Meeting Abstracts

Abstract Number: 0467 • ACR Convergence 2024
Lung Involvement in Early Rheumatoid Arthritis, Analysis of ERA UCLouvain Brussels FINDRA Cohort
FROIDURE Antoine¹, DOYEN Marie², PERROT Marie¹, GHAYE Benoit³, SAPART Emilie⁴, BEARZATTO Bertrand⁵, DURANT Jean-François⁵, AMBROISE Jérôme⁵, GALA Jean-Luc⁵, ZAN Deniz³, AVRAMOVSKA Aleksandra⁴, SOKOLOVA Tatiana⁴, KOENIG Sandra² and DUREZ Patrick⁴, ¹Pulmonology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ²Rheumatology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³Radiology department, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ⁴Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, ⁵Institute de Recherche Expérimentale et Clinique (IREC), Cliniques Universitaires Saint-Luc - Université Catholique de Louvain (UCL), Brussels, Belgium
Background/Purpose: The prevalence of lung involvement in rheumatoid arthritis (RA) remains elusive. We set up a prospective study to detect ILD, bronchiolitis and nodules in…
Abstract Number: 0388 • ACR Convergence 2024
The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry
Samantha Morin¹, KAREN BEATTIE², Roxana Bolaria³, Tania Cellucci⁴, Gaelle Chedeville⁵, Amieleena Chhabra⁶, Paul Dancey⁷, Tommy Gerschman⁸, Liane Heale⁹, Julie Herrington², Adam Huber¹⁰, Mehul Jariwala¹¹, Jean-Philippe Proulx-Gauthier¹², Dax Rumsey¹³, Heinrike Schmeling¹⁴, Jaime Guzman¹⁵ and Michelle Batthish⁴, and CAPRI Registry Investigators, ¹McMaster University, Hamilton, Canada, ²McMaster University, Hamilton, ON, Canada, ³Victoria Arthritis Center, Victoria, BC, Canada, ⁴McMaster Children's Hospital, Hamilton, ON, Canada, ⁵The Montreal Children's Hospital, Montreal, QC, Canada, ⁶University of British Columbia, Penticton, BC, Canada, ⁷Memorial University, St. John's, Canada, ⁸University of British Columbia - Vancouver, North Vancouver, BC, Canada, ⁹McMaster University, Oakville, ON, Canada, ¹⁰IWK Health Centre, Halifax, NS, Canada, ¹¹Jim Pattison Children's Hospital, Saskatoon, Canada, ¹²CHU de Quebec - Universite Laval, Quebec, QC, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Recent evidence has linked abnormal body weight, underweight or obesity, with poor disease outcomes in adults with inflammatory arthritis. Yet, little is known about…
Abstract Number: 0548 • ACR Convergence 2024
Associations and Impact of Kinesiophobia on Patient Reported Outcomes and Performance-based Mobility Measures in Patients with Axial Spondyloarthritis
David Kiefer¹, Juergen Braun², Uta Kiltz³, Niklas Kolle¹, Lucia Schneider¹, Ioana Andreica⁴, Bjoern Buehring⁵, Philipp Sewerin⁶, Imke Redeker⁷, Styliani Tsiami⁸, Susanne Herbold⁹ and Xenofon Baraliakos⁸, ¹Ruhr-Universität Bochum; Rheumazentrum Ruhrgebiet, Herne, Germany, ²Rheuma Praxis, Ruhr-University Bochum, Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, ⁴Rheumazentrum Ruhrgebiet Herne, Herne, Germany, ⁵Bergisches Rheuma-Zentrum Wuppertal; Ruhr-Universität Bochum, Wuppertal, Germany, ⁶Ruhr-Universität Bochum, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷Ruhr Universität Bochum, Bochum, Germany, ⁸Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ⁹Rheumazentrum Ruhrgebiet, Herne, Herne, Germany
Background/Purpose: Kinesiophobia, defined as the fear of movement, poses a significant barrier to effective rehabilitation, functional recovery, and adequate physical activity. To investigate the impact…
Abstract Number: 0558 • ACR Convergence 2024
Patient Diagnostic Journey and Time to Diagnosis in Axial Spondyloarthritis: A Retrospective Cohort Study Using US Claims Data
Maureen Dubreuil¹, Marina Magrey², Kathrin Haeffs³, Evgueni Ivanov⁴ and Julie Gandrup Horan⁵, ¹Section of Rheumatology, Boston University School of Medicine, Boston, MA, ²Case Western Reserve University School of Medicine/University Hospitals, Richfield, OH, ³UCB Pharma, Monheim, Germany, ⁴UCB Pharma, Bulle, Switzerland, ⁵UCB Pharma, Slough, United Kingdom
Background/Purpose: The journey to axial spondyloarthritis (axSpA) diagnosis is often prolonged and challenging, resulting in poor clinical, psychological, social, and economic outcomes.1 Understanding the factors…
Abstract Number: 0565 • ACR Convergence 2024
Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study
Anthony Lichaa¹, Pauline KRUG¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive disease, characterized by chronic inflammation and progressive structural damage. However, the kinetic of progression to ankylosis and much…
Abstract Number: 0555 • ACR Convergence 2024
The Effect of Alcohol Consumption on Clinical Outcomes and Structural Damage in Patients with Axial Spondyloarthritis: A Systematic Literature Review and Meta-Analysis
Sinead Maguire¹, Nigil Haroon², Robert Inman³, Melanie Anderson⁴, Evelyne Gendron⁵ and Sindhu R. Johnson⁶, ¹University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Toronto, Canada, ²Department of Medicine/Rheumatology, University Health Network, Schroeder Arthritis Institute, University of Toronto, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The Institute for Education Research, Library and Information Services, University Health Network, Toronto, ON, Canada, ⁵University of Toronto, University Health Network, Schroeder Arthritis Institute, Department of Rheumatology, Quebec City, QC, Canada, ⁶University of Toronto, Toronto, Canada
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic progressive inflammatory disease characterized by the involvement of the axial skeleton. Alcohol consumption (AC) is a modifiable lifestyle…
Abstract Number: 0529 • ACR Convergence 2024
Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data
Yinan Huang¹, Shadi Bazzazzadehgan², Sebastian Bruera³ and Sandeep Agarwal³, ¹University of Mississippi School of Pharmacy, Oxford, MS, ²University of Mississippi School of Pharmacy, Oxford, ³Baylor College of Medicine, Houston
Background/Purpose: Individuals with rheumatoid arthritis (RA) may discontinue b/tsDMARDs due to treatment failure, adverse events or costs. Little is known about b/tsDMARDs discontinuation among Medicare…
Abstract Number: 0557 • ACR Convergence 2024
What Factors Are Associated with Pain Intensity in Axial Spondyloarthritis? Results from the International Map of Axial Spondyloarthritis (IMAS)
Marco Garrido-Cumbrera¹, Victoria Navarro Compán², Fernando Andres Sommerfleck³, Christine Bundy⁴, Souzi Makri⁵, José Correa-Fernández⁶, Shashank Akerkar⁷, Jo Lowe⁸, Elie Karam⁹ and Denis Poddubnyy¹⁰, ¹Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain / Spanish Federation of Spondyloarthritis Patient Associations (CEADE), Madrid, Spain, Seville, Spain, ²La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain, ³Sanatorio Julio Mendez, Buenos Aires, Argentina, ⁴Cardiff University, Cardiff, UK, Cardiff, United Kingdom, ⁵Cyprus League for People with Rheumatism (CYLPER), Nicosia, Cyprus, Nicosia, Cyprus, ⁶Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain, Seville, Spain, ⁷Mumbai Arthritis Clinic, Mumbai, India, Mumbai, India, ⁸Axial Spondyloarthritis International Federation, London, United Kingdom, ⁹Canadian Spondylitis Association (CSA), Toronto, Canada, Toronto, Canada, ¹⁰Charite-Universitatsmedizin Berlin, Berlin, Germany
Background/Purpose: Severe pain in patients with axial spondyloarthritis (axSpA) can cause deterioration in their physical and mental health. The aim is to investigate factors associated…
Abstract Number: 0541 • ACR Convergence 2024
Measurement Properties of Disease Activity Instruments in Peripheral Spondyloarthritis. an Analysis in the CRESPA Trial
Clementina López Medina¹, Anna Molto², Dafne Capelusnik³, Philippe Carron⁴, Casper Webers⁵, Filip Van den Bosch⁶, Annelies Boonen⁷ and Sofia Ramiro⁸, ¹Reina Sofia University Hospital, Cordoba, Spain, ²Groupe Hospitalier Cochin, AP-HP, Paris, France, ³Tel Aviv Sourasky Medical Center, Ramat Gan, Israel, ⁴UZ Gent, Gent, Belgium, ⁵Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, ⁶Ghent University Hospital, Ghent, Belgium, ⁷Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center; Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands, ⁸Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Understanding the best-performing disease activity measure and response criterion in peripheral spondyloarthritis (pSpA) is crucial for the development of future meaningful clinical studies. The…
Abstract Number: 0528 • ACR Convergence 2024
Consequences of Switching Originator Biological Therapies to Its Biosimilars in Patients with Immune-mediated Diseases in a Mexican Cohort
Sandra Carrillo¹, Daniel Xibille², Martha Mariana Castañeda-Martínez³, Alfredo Reyes⁴, Brian garcia-Arellano⁵, Edgar Vega Chávez⁶, Carlos vidal Montiel Castañeda⁵, Gabriel Carmona Lara⁶ and Gilberto De Hoyos⁵, ¹Hospital Angeles Lindavista, Mexico City, Distrito Federal, Mexico, ²Servicios de Salud de Morelos, Cuernavaca, Morelos, Mexico, ³ISSSTE, Monterrey, Mexico, ⁴ISSSTE, Ciudad de México, Mexico, ⁵ISSSTE, Ciudad de México, Distrito Federal, Mexico, ⁶ISSSTE, Ciudad de mexico, Distrito Federal, Mexico
Background/Purpose: Biological agents such as the TNF-α inhibitors have had a positive impact on the treatment of many chronic autoimmune diseases (AIDs), such as Rheumatoid…
Abstract Number: 0458 • ACR Convergence 2024
Long-Term Outcomes in Seronegative Rheumatoid Arthritis
Bradly Kimbrough¹, Cynthia Crowson², Sara Achenbach³ and Elena Myasoedova², ¹Mayo Clinic Rochester, Rochester, MN, ²Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, Rochester, MN
Background/Purpose: Seronegative rheumatoid arthritis (RA) is a heterogenous disease distinct from seropositive RA regarding genetic risk factors, pathobiology, and prognosis. Notably, recent studies have shown…
Abstract Number: 0537 • ACR Convergence 2024
Evaluating the Usage of Janus Kinase Inhibitors in Rheumatology and Its Impact on Cardiovascular Risk
Knkush Hakobyan¹, Talar Acob², Mesrop Aleksanyan³, Tigran Kakhktsyan³, Omar Jumaah³ and Sajina Prabhakaran⁴, ¹Capital Health medical center, Princeton, NJ, ²College of medicine-university of Baghdad, Plainsboro Township, NJ, ³Capital Health Medical Center, Trenton, ⁴Capital health Rheumatology specialists, Newtown, PA
Background/Purpose: Janus kinase (JAK) inhibitors have been widely used in treatingrheumatological conditions like rheumatoid arthritis and psoriatic arthritis. Despite theirefficacy, there are concerns regarding major…
Abstract Number: 0568 • ACR Convergence 2024
Coexistence of Raynaud’s Phenomenon, Morphea or Scleroderma in Spondyloarthritis Patients: Insights from a Retrospective Cohort Study Highlighting a Unique Phenotype
Ameesh Dev, Cary Roy, Deepak Jagannath, Alexandra Cloutet and Sarah Kazzaz, Houston Methodist Hospital, Houston, TX
Background/Purpose: Spondyloarthritis (SpA) is a heterogeneous group of inflammatory arthritides that includes ankylosing spondylitis (AS), psoriatic arthritis (PsA), enteropathic-related arthritis, reactive arthritis, and undifferentiated SpA.…
Abstract Number: 0510 • ACR Convergence 2024
Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis
Ahmad Alsaber¹, Adeeba Alherz², Huda Khraiss³, Ghaydaa Aldabie⁴, balqees alawadhi⁵, Jiazhu Pan⁶, Adel Alawadhi⁷, KHULOUD MOHAMMED⁸, Hoda Tarakmeh⁹, Aqeel Muhanna¹⁰, Yaser Ali¹¹ and mohammad Khudadah¹², and Kuwait Registry for Rheumatic Diseases (KRRD), ¹American University of Kuwait, Kuwait, Kuwait, ²Al-Amiri Hospital, Kuwait, Kuwait, ³Monash University, Melbourne, Queensland, Australia, ⁴ministry of health kuwait, kuwait, Kuwait, ⁵The Public Authority for Applied Education and Training (PAAET), Kuwait, Al Asimah, Kuwait, ⁶University of Strathclyde, Glasgow, Scotland, United Kingdom, ⁷Kuwait University, Kuwait, Kuwait, ⁸Farwaniya Hospital, Kuwait, Kuwait, ⁹MOH Kuwait, Kuwait, Kuwait, ¹⁰Ministry of Health, Kuwait, Al Farwaniyah, Kuwait, ¹¹Mubarek Al Kabeer Hospital, Kuwait city, Kuwait, ¹²ministery of health, kuwait, Kuwait
Background/Purpose: This study aims to employ various machine learning tools to predict the responses of rheumatoid arthritis (RA) patients to biologic treatments, using data from…
Abstract Number: 0392 • ACR Convergence 2024
Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes
Geoffrey Thiele¹, Panteha Hayati Rezvan², Michal Cidon², Carlos Hunter³, Michael Duryee³, Ted Mikuls³ and Geoffrey Thiele³, ¹Children's Hospital of Los Angeles, Omaha, NE, ²Children's Hospital of Los Angeles, Los Angeles, CA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Studies of rheumatoid arthritis (RA) have shown that malondialdehyde-acetaldehyde (MAA) protein adducts and anti-MAA immune responses play a pathogenic role in disease progression. Expression of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].